MarketPeel
Insider Trading Intelligence
Pricing
…
CT

Cameron Turtle

SYRE
CHIEF EXECUTIVE OFFICER · SPYRE THERAPEUTICS, INC. · CIK 0001758363
FILING MIX · LIFETIME32%/68%
BUYS
28
SELLS
60
TOTAL VALUE
$11.66M
COMPANIES
4
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
658,484
AVG SELL PX
$43.84
TRADE KIND
SHOWING 88 / 88
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
36 backtested trades · 8 horizons · 56 pending
Forward-return performance of every backtestable P/S trade by Cameron Turtle, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d36+33.33%+2.87%+0.83%+2.03%+1.47%1.47
14d36+22.22%+7.11%+1.23%+5.89%+6.58%3.33
30d36+16.67%+11.27%+1.11%+11.24%+9.79%3.33
60d36+13.89%+23.46%+2.36%+19.52%+24.91%5.25
90d36(6 pending)+16.67%+43.08%+4.08%+36.86%+42.12%—
180d36(12 pending)+20.83%+80.20%+13.83%+59.67%+33.11%—
1y36(19 pending)+23.53%+37.35%+32.91%+4.44%-2.62%—
2y36(19 pending)+100.00%-72.63%+25.72%-98.35%-95.35%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SYRE · 582,540 shares · as of Jul 1, 2026
0186,727373,454560,180746,90720252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 28 buys / 60 sellsCOVERAGE · 27 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
590$88.91$52.5K582,540Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,176$87.44$889.8K587,364Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,234$88.12$373.1K583,130Jul 1, 2026Jul 2, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,557$69.40$246.9K608,983Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,149$70.50$574.5K600,834Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,294$71.38$235.1K597,540Jun 1, 2026Jun 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,700$74.23$126.2K612,840May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,600$70.77$254.8K618,640May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$71.76$71.8K617,640May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
300$74.96$22.5K612,540May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,300$69.54$368.6K622,240May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,100$73.14$226.7K614,540May 1, 2026May 1, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,344$49.20$607.3K630,196Apr 1, 2026Apr 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,656$49.92$132.6K627,540Apr 1, 2026Apr 3, 2026 ↗View →
GLTO
GALECTO, INC.
PURCHASEGRANT
Stock grant
37,313——37,313Mar 23, 2026Mar 25, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,900$41.73$246.2K651,640Mar 2, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,100$42.49$386.7K642,540Mar 2, 2026Mar 3, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
957$31.82$30.5K671,583Feb 2, 2026Feb 4, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,043$32.87$461.6K657,540Feb 2, 2026Feb 4, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
528,000——528,000Jan 9, 2026Jan 13, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,191$31.79$69.7K672,007Jan 2, 2026Jan 6, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100$32.39$3.2K671,907Jan 2, 2026Jan 6, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,709$30.47$387.2K674,198Jan 2, 2026Jan 6, 2026 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,995$28.73$315.9K690,912Dec 1, 2025Dec 3, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,005$29.83$119.5K686,907Dec 1, 2025Dec 3, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
16,845$23.66$398.6K701,907Nov 3, 2025Nov 5, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,155$23.13$651.2K718,752Nov 3, 2025Nov 5, 2025 ↗View →
ORKA
ORUKA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 2, 2025Jun 3, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
370,000——370,000Jan 15, 2025Jan 17, 2025 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
400$9.82$3.9K746,907Feb 15, 2024Feb 20, 2024 ↗View →
SYRE
SPYRE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
277,750——277,750Feb 1, 2024Feb 2, 2024 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
6,000$0.34$2.0K26,068Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
6,000$0.16$96032,068Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
7,500——255,500Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
8,563$69.94$598.9K12,568Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
6,000——31,766Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
6,000——56,042Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
7,500$17.00$127.5K20,068Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
10,937$69.34$758.3K21,131Dec 28, 2020Dec 29, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
742$47.23$35.0K12,568Nov 25, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
742$17.00$12.6K13,310Nov 25, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
742——263,000Nov 25, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
4,258——263,742Nov 24, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
4,258$47.00$200.1K12,568Nov 24, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
4,258$17.00$72.4K16,826Nov 24, 2020Nov 25, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500$42.05$105.1K12,568Nov 5, 2020Nov 5, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500——268,000Nov 5, 2020Nov 5, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,500$17.00$42.5K15,068Nov 5, 2020Nov 5, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
12,442$37.59$467.8K14,626Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,500$17.00$42.5K15,068Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
6,000$0.16$96021,068Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
6,000——37,766Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500——270,500Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
6,000$0.34$2.0K27,068Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,058$38.24$78.7K12,568Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
6,000——62,042Sep 30, 2020Oct 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,500$17.00$42.5K15,068Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500$42.01$105.0K12,568Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500——273,000Sep 18, 2020Sep 22, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,500$17.00$42.5K15,068Sep 15, 2020Sep 16, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500$37.06$92.7K12,568Sep 15, 2020Sep 16, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,500——275,500Sep 15, 2020Sep 16, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000——43,766Sep 11, 2020Sep 15, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,000$0.34$68014,568Sep 11, 2020Sep 15, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000$35.02$70.0K12,568Sep 11, 2020Sep 15, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
2,745——12,568Sep 1, 2020Sep 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
6,000——68,042Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
4,000$0.34$1.4K19,823Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
4,000——45,766Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
9,700$32.65$316.7K10,123Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
300$33.17$10.0K9,823Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
6,000$0.16$96015,823Jun 30, 2020Jul 2, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
74,042——74,042May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
49,766——49,766May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASEGRANT
Stock grant
1,082——1,082May 19, 2020May 21, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000$32.01$64.0K9,823Apr 27, 2020Apr 28, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000——278,000Apr 27, 2020Apr 28, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,000$17.00$34.0K11,823Apr 27, 2020Apr 28, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
8,000$27.04$216.4K9,823Apr 8, 2020Apr 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
8,000$17.00$136.0K17,823Apr 8, 2020Apr 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
8,000——280,000Apr 8, 2020Apr 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
2,000$17.00$34.0K11,823Feb 11, 2020Feb 13, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000$37.28$74.6K9,823Feb 11, 2020Feb 13, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
2,000——288,000Feb 11, 2020Feb 13, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
4,802$34.71$166.7K9,823Jan 8, 2020Jan 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
10,000——290,000Jan 8, 2020Jan 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
PURCHASE
See Remarks
10,000$17.00$170.0K22,630Jan 8, 2020Jan 10, 2020 ↗View →
BBIO
BRIDGEBIO PHARMA, INC.
SALE
See Remarks
8,005$34.17$273.5K14,625Jan 8, 2020Jan 10, 2020 ↗View →
Other insiders · SYRE
Loading peer insiders…
About this filer
CIK 0001758363
ROLE
Chief Executive Officer
PRIMARY
SYRE
COMPANIES
4
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001758363DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback